ELCO Management’s AbbVie ABBV Stock Holding History

ELCO Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.72M	Sell	17,124 -47	-0.3%	-$10.4K	1.79%	14
2025 Q4	$3.92M	Sell	17,171 -155	-0.9%	-$35.3K	2.47%	11
2025 Q3	$4.01M	Sell	17,326 -5	-0%	-$1.02K	2.09%	14
2025 Q2	$3.22M	Sell	17,331 -380	-2%	-$70.6K	1.69%	16
2025 Q1	$3.71M	Sell	17,711 -205	-1%	-$39.9K	2.05%	12
2024 Q4	$3.18M	Sell	17,916 -140	-0.8%	-$25.7K	1.67%	12
2024 Q3	$3.57M	Hold	18,056	–	–	1.92%	12
2024 Q2	$3.1M	Hold	18,056	–	–	1.8%	12
2024 Q1	$3.29M	Hold	18,056	–	–	2%	12
2023 Q4	$2.8M	Hold	18,056	–	–	1.84%	13
2023 Q3	$2.69M	Sell	18,056 -65	-0.4%	-$9.54K	1.94%	12
2023 Q2	$2.44M	Sell	18,121 -190	-1%	-$27.9K	1.77%	15
2023 Q1	$2.92M	Buy	18,311 +21	+0.1%	+$3.21K	2.12%	13
2022 Q4	$2.96M	Hold	18,290	–	–	2.22%	9
2022 Q3	$2.46M	Sell	18,290 -80	-0.4%	-$11.5K	1.95%	12
2022 Q2	$2.81M	Sell	18,370 -130	-0.7%	-$19.9K	2.31%	11
2022 Q1	$3M	Hold	18,500	–	–	2.04%	14
2021 Q4	$2.5M	Hold	18,500	–	–	1.79%	16
2021 Q3	$2M	Hold	18,500	–	–	1.54%	18
2021 Q2	$2.08M	Hold	18,500	–	–	1.55%	18
2021 Q1	$2M	Hold	18,500	–	–	1.81%	16
2020 Q4	$1.98M	Hold	18,500	–	–	1.71%	17
2020 Q3	$1.62M	Hold	18,500	–	–	1.32%	23
2020 Q2	$1.82M	Hold	18,500	–	–	1.53%	18
2020 Q1	$1.41M	Hold	18,500	–	–	1.47%	21
2019 Q4	$1.64M	Hold	18,500	–	–	0.99%	29
2019 Q3	$1.4M	Hold	18,500	–	–	0.84%	36
2019 Q2	$1.34M	Hold	18,500	–	–	0.74%	37
2019 Q1	$1.49M	Hold	18,500	–	–	0.88%	33
2018 Q4	$1.71M	Hold	18,500	–	–	1.16%	27
2018 Q3	$1.75M	Hold	18,500	–	–	0.92%	35
2018 Q2	$1.71M	Hold	18,500	–	–	0.92%	34
2018 Q1	$1.75M	Hold	18,500	–	–	1.03%	28
2017 Q4	$1.79M	Hold	18,500	–	–	0.99%	31
2017 Q3	$1.64M	Hold	18,500	–	–	0.93%	33
2017 Q2	$1.34M	Hold	18,500	–	–	0.78%	42
2017 Q1	$1.21M	Hold	18,500	–	–	0.64%	55
2016 Q4	$1.16M	Hold	18,500	–	–	0.64%	52
2016 Q3	$1.17M	Buy	+18,500	New	+$1.2M	0.47%	60

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ELCO Management's ABBV Position: Q1 2026 in Review

ELCO Management reduced its AbbVie (ABBV) stake by 0.27% in Q1 2026, selling an estimated $10.4K and leaving 17,124 shares worth $3.72M. The position accounts for 1.79% of the portfolio, ranked #14.

ELCO Management first reported a position in ABBV in Q3 2016 and has held it in 39 quarters since. The position peaked at $4.01M in Q3 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

ELCO Management held 17,124 shares of AbbVie worth $3.72M as of Q1 2026.
ELCO Management sold 47 AbbVie shares in Q1 2026, an estimated $10.4K.
AbbVie made up 1.79% of ELCO Management's portfolio in Q1 2026, its #14 holding.
ELCO Management first reported a position in AbbVie in Q3 2016 and has held it in 39 quarters since.
ELCO Management's AbbVie position peaked at $4.01M in Q3 2025.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on ELCO Management's 13F filing for Q1 2026, filed 24 Apr 2026.